AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Anti-tuberculosis drug

Summary

PPI-benzimidazole analogues for the treatment of multidrug-resistant tuberculosis.

Technology Benefits

Active against multidrug-resistant tuberculosis
Small molecule
Tested in-vitro and in-vivo
SAR data available

Technology Application

new drug to treat Mtb infections.

Detailed Technology Description

he inventors were able to demonstrate that lansoprazole and derivatives thereof exhibit growth inhibiting properties against intracellular Mtb. In particular, it has been proven that the reduced form lansoprazole sulfide is the active moiety. Yet, lansoprazole is not metabolized in a sufficient amount to serve as a prodrug. Thus, the inventors propose lansoprazole sulfide (LPZS) as a new drug to treat Mtb infections.

Type of Cooperation

Licensing

Application Date

26/01/2016 00:00:00

Application No.

EP20160701631 20160126

Classes

- international:
A61K31/4439; A61K45/06; A61P31/06
- cooperative:
default
A61K31/4439; A61K45/06; A61P31/06; C07D401/12; A61K2300/00

C-sets
A61K31/4439, A61K2300/00

Others

Patent application

ID No.

5126

Country/Region

Germany

For more information, please click Here